ImmunoPET Imaging of Human CA6
Research Manuscript Sample Work
A first-in-human imaging manuscript built around two patients
This sample is an original research manuscript reporting the first use in humans of a copper-64-labelled antibody fragment designed to image CA6 expression by positron emission tomography (PET). It follows the usual structure of an early-phase clinical imaging paper: a structured abstract (Purpose, Methods, Results, Conclusion), then an introduction and detailed materials and methods covering the tracer, cell lines, radiochemistry, safety monitoring, imaging and immunohistochemistry (IHC). It is written for nuclear medicine physicians, oncologists and teams developing antibody-drug conjugates (ADCs). These readers want to know whether a tracer is safe and whether its uptake matches tissue expression of the target.
Why ADC therapy needs a non-invasive companion diagnostic
The introduction explains that ADCs use an antibody to deliver a cytotoxic payload selectively to cells carrying a tumour-associated antigen. It cites the regulatory approvals of brentuximab vedotin (targeting CD30) in 2011 and ado-trastuzumab emtansine (targeting HER2) in 2013, and notes that more than 60 other ADCs were in clinical trials. Because an ADC only works where its antigen is present, measuring antigen levels before treatment is essential. Biopsy followed by IHC is open to sampling error and rarely covers every metastatic site. A PET tracer could select patients for treatment and later monitor their response.
The target here is CA6, a sialoglycotope on MUC1. It is found on breast, ovarian, cervical, lung and pancreatic tumours, with limited normal expression in fallopian tube epithelium, inner urothelium and type 2 pneumocytes. The matching therapy is huDS6-DM4 (SAR566658), which delivers a maytansinoid that disrupts microtubules.
From antibody fragment to 64Cu tracer
The tracer, BFab, is a fragment of roughly 50 kDa engineered from the variable domains of the humanised huDS6 antibody, with a histidine tag for purification. It was manufactured to pharmaceutical grade by Sanofi. The authors chose a fragment because engineered fragments clear from the circulation faster than full antibodies, which suits copper-64 with its 12.7-hour half-life. BFab was conjugated to the chelator DOTA and radiolabelled. Preclinical work in tumour-bearing mice had shown an uptake ratio 1.6-fold higher in CA6-positive than in CA6-negative tumours at 24 hours. CA6-positive WISH cells and CA6-negative A2780 ovarian carcinoma cells served as the in vitro controls.
Patients, safety monitoring and what the scans showed
- Participants: two women, aged 47 and 62, previously treated by resection and chemotherapy for ovarian or breast cancer.
- Imaging: [18F]FDG PET/CT first, then 64Cu-BFab (5.5–11.7 mCi) one to four weeks later, with whole-body PET/CT at 1 and 24 hours.
- Safety: blood pressure, ECG, oxygen saturation, heart rate and full blood count recorded before injection and at intervals up to 24 hours afterwards. Two nuclear medicine physicians reviewed every scan.
- Results: the tracer was well tolerated, with no adverse effects observed, and no significant tracer uptake was seen in either patient. FDG imaging in the breast cancer patient showed metastases in the liver, bilateral hila and thoracic spine.
- FDG findings in the ovarian patient: no definite active disease, apart from a mildly FDG-avid para-aortic lymph node judged likely reactive (its biopsy was negative), even though biopsy had confirmed disease in the omentum, myometrium, serosa, fallopian tubes and both ovaries. The manuscript sets out this mismatch between imaging and pathology without trying to explain it away.
- Tissue: after chemotherapy, the liver metastasis had an IHC H-score of 35. The ovarian patient's lymph node scored 80 before chemotherapy and 35 after.
Reporting a negative pilot result clearly
The manuscript handles a result with no detectable tracer uptake honestly. It states that uptake was absent, reports the relatively low post-chemotherapy H-scores alongside it, and concludes only that the tracer was safe and that more studies are needed to judge its diagnostic value. The methods record the date of every scan and biopsy and the injected activity and protein mass, so readers can rebuild the sequence of events. That level of detail is what reviewers expect when interpreting a small first-in-human cohort. A submission-ready version would also discuss the limitations directly: only two participants, biopsies taken at different times from the scans, and the possibility that chemotherapy had reduced CA6 expression.
Manuscripts of this kind should follow ICMJE recommendations on ethics approval, consent and trial registration. Pubrica's physician manuscript writing service supports authors drafting such papers. Technical accuracy in the radiochemistry and imaging sections can be checked through scientific editing, and a pre-submission peer review tests the interpretation before journal referees see it. This page is a writing sample, not clinical guidance on cancer imaging.
Questions about this sample
Why did the investigators use an antibody fragment instead of a full antibody?
Engineered antibody fragments clear from the circulation faster than intact antibodies. That shortens the time needed to reach useful tumour-to-background contrast and suits copper-64, with its 12.7-hour half-life. BFab, at about 50 kDa, was derived from the humanised huDS6 antibody that also forms the targeting part of the CA6-directed drug conjugate.
What did the 64Cu-BFab scans show in the two patients?
The tracer was well tolerated, with no adverse effects observed, but neither patient showed significant uptake. Tissue analysis found relatively low CA6 expression after chemotherapy, with H-scores of 35 in both patients' post-treatment samples, which the manuscript reports alongside the imaging results without overstating what they mean.
How was CA6 expression measured in tissue?
By immunohistochemistry on biopsy and surgical samples, quantified as an H-score that reflects the intensity of membrane staining. The staining used SAR566658 as the primary antibody with a biotinylated anti-DM4 secondary antibody on an automated platform. Haematoxylin-eosin-saffron slides were prepared alongside for comparison.
What type of manuscript is this sample?
It is an original first-in-human research article, not a literature review. It reports a pilot imaging study in two patients, with a structured abstract, a rationale grounded in ADC development, detailed radiochemistry and imaging methods, safety monitoring and tissue correlation. It is useful as a model for authors reporting small early-phase tracer studies.
Give yourself the academic edge today
Each order includes
- On-time delivery or your money back
- A fully qualified writer in your subject
- In-depth proofreading by our Quality Control Team
- 100% confidentiality, the work is never re-sold or published
- Standard 7-day amendment period
- A paper written to the standard ordered
- A detailed plagiarism report
- A comprehensive quality report
Enquire Now
